問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

Recruiting

List

1450Cases

2025-12-15 - 2028-06-29

Phase I/II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2025-06-01 - 2034-08-15

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2020-04-01 - 2025-11-26

Phase III

Completed
A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

  • Condition/Disease

    Previously Untreated, Locally Advanced Non-small Cell Lung Cancer

  • Test Drug

    OPDIVO (nivolumab) Injection 10mg/mL OPDIVO (nivolumab) Injection 10mg/mL YERVOY (ipilimumab) Injection 5mg/mL YERVOY (ipilimumab) Injection 5mg/mL

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

2017-01-26 - 2025-12-31

Phase IV

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2020-01-01 - 2025-12-31

Phase III

Completed
A Multicenter, Single Arm, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

  • Condition/Disease

    Neuromyelitis Optica Spectrum Disorder (NMOSD)

  • Test Drug

    ENSPRYNG 120mg for SC Injection

Participate Sites
4Sites

Recruiting4Sites

2020-05-31 - 2028-05-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2018-08-01 - 2026-12-01

Phase III

Active
A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ALECTINIB VERSUS ADJUVANT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB (TUMORS ≥ 4 CM) TO STAGE IIIA ANAPLASTIC LYMPHOMA KINASE-POSITIVE NON-SMALL CELL LUNG CANCER

  • Condition/Disease

    NON-SMALL CELL LUNG CANCER (NSCLC)

  • Test Drug

    RO5424802(Alctinib)、capsule、 150mg

Participate Sites
9Sites

Recruiting8Sites

2020-04-01 - 2026-09-01

Phase I/II

Active
A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Healthy Volunteers and Patients with Hemophilia A

  • Condition/Disease

    Hemophilia A

  • Test Drug

    NXT007

Participate Sites
5Sites

Recruiting5Sites

2021-03-01 - 2026-12-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

2024-12-30 - 2031-06-30

Phase II

Active
THE RETIRE TRIAL: A RANDOMIZED PHASE 2 TRIAL OF ADOPTIVE THERAPY WITH TREG ADOPTIVE CELL TRANSFER (TRACT) TO PREVENT REJECTION IN LIVING DONOR KIDNEY TRANSPLANT RECIPIENTS

  • Condition/Disease

    Kidney Transplantation

  • Test Drug

    TRK-001

Participate Sites
4Sites

Recruiting4Sites

1 97 98 99 100 101 145
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB